NEW YORK, March 6 - EmerGen, a privately held discovery company based in Salt Lake City, said on Wednesday that it has appointed Richard Jackson president and CEO.
According to EmerGen, Jackson will guide the company as it develops partnerships with pharmaceutical and biotech companies and works toward drug development.
Jackson was previously senior vice president of discovery research at Wyeth-Ayerst, where he was involved in developing products for women's health, neurological disease, infectious disease, and oncology. Before that, Jackson was senior vice president of R&D at Atrix Laboratories, a Fort Collins, Colo. biotech firm.
EmerGen focuses on genetic and genomic research in women's health and reproductive medicine. The company has collected a library of patient samples related to pregnancy complications and birth defects.
Oxford GlycoSciences said on Tuesday that Don DeGolyer, president of global therapeutics, would join the company's board of directors.
DeGolyer has been with OGS since September 2001. His role involves leading the company's drug-commercialization efforts.
Before joining Oxford, he was VP of marketing at ParkStone Medical Information Systems, and also worked in marketing and sales with Pfizer and Johnson & Johnson.
Cepheid said on Monday that it had named Tony Godfrey of the University of Pittsburgh Cancer Institute to the company's scientific advisory board.
Godfrey, who is assistant professor of surgery and human genetics at the cancer institute, researches DNA-based methods for early cancer detection. His focus includes detecting micrometastic disease in lung and esophageal cancer.
Godfrey was previously manager of the Genome Analysis Core Facility at the University of California at San Francisco. He is trained as a molecular biologist and biochemist. Cepheid, headquartered in Sunnyvale, Calif., is publicly owned.
Promoted? Changing jobs? GenomeWeb wants to know. Help us keep track of you by e-mailing us at [email protected] PEOPLE, a roundup of personnel comings and goings in genomics, appears each Wednesday.